This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BONORA, E. Articles by MUGGEO, M. Search for Related Content PubMed PubMed Citation Articles by BONORA, E. Articles by MUGGEO, M.

Plasma Concentrations of Growth Hormone during Hyperglycemic Clamp with or without Somatostatin Infusion in Obese Subjects^*

Cattedra di Malattie del Metabolismo and Istituto di Chimica e Microscopia Clinica (A.C.), University of Verona Verona, Italy

Address all correspondence and requests for reprints to: Dr. Enzo Bonora, Cattedra di Malattie del Metabolismo, Università di Verona, Ospedale Policlinico I 37134, Verona, Italy.

It is known that obese subjects have a blunted GH secretory response to stimulation, but little is known about the inhibition of GH secretion in obesity. The present study was designed to evaluate the effects of obesity on the suppression of GH by hyperglycemia and/or somatostatin. Plasma GH concentrations were measured in eight nondiabetic obese subjects and eight nonobese healthy controls during a 4-h hyperglycemic clamp. During the third hour synthetic cyclic somatostatin-14 was infused at the rate of 2.5 nmol/min. Baseline plasma GH levels were similar in obese and nonobese subjects (0.9 ± 0.1 vs. 0.8 ± 0.2 µg/L; mean ± SEM). In the last 20 min of the glucose infusion period preceding somatostatin administration (100–120 min of the study) plasma GH averaged 0.8 ±0.1 µg/L in obese patients and 0.4 ± 0.1 µg/L in control subjects (P < 0.01), with a reduction of 6 ± 5% in the former and 35 ± 10% in the latter (P < 0.01). In both groups somatostatin infusion did not result in a further decrease in plasma GH. Discontinuation of the somatostatin infusion resulted in a rise in both groups; the increase was higher in nonobese subjects (8.1 ± 3.8 vs. 2.3 ± 0.9 µg/L in the period 220–240 min; P = NS). These results suggest that in human obesity, hyperglycemia has a diminished inhibitory effect on GH secretion, and somatostatin administration has no additional effect in either obese or nonobese nondiabetic subjects.

^* This work was supported by Grants 85.00502.04 and 86.00102.04 from Consiglio Nazionale delle Ricerche, Italy, and grants from Ministero della Pubblica Istruzione, Italy.

Received March 3, 1989.

This article has been cited by other articles:

				P. U. Freda, A. T. Nuruzzaman, C. M. Reyes, R. E. Sundeen, and K. D. Post Significance of "Abnormal" Nadir Growth Hormone Levels after Oral Glucose in Postoperative Patients with Acromegaly in Remission with Normal Insulin-Like Growth Factor-I Levels J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 495 - 500. [Abstract] [Full Text] [PDF]

				P. U. Freda, K. D. Post, J. S. Powell, and S. L. Wardlaw Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3808 - 3816. [Abstract] [Full Text]

				S. Grottoli, M. Procopio, M. Maccario, M. Zini, S. E. Oleandri, F. Tassone, R. Valcavi, and E. Ghigo In Obesity, Glucose Load Loses Its Early Inhibitory, But Maintains Its Late Stimulatory, Effect on Somatotrope Secretion J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2261 - 2265. [Abstract] [Full Text] [PDF]